Acr Convergence 2024. (“capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through rna. The floor plan provides a visual map of the entire event.
We are pleased to announce that we will attend acr convergence 2024, the world’s premier rheumatology event. Targeted exosite inhibition of sting activation of tbk1 selectively blocks type i interferon and nfκb responses for treatment of.
